GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Equity-to-Asset

Axsome Therapeutics (Axsome Therapeutics) Equity-to-Asset : 0.26 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Axsome Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $144.0 Mil. Axsome Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $545.7 Mil. Therefore, Axsome Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.26.

The historical rank and industry rank for Axsome Therapeutics's Equity-to-Asset or its related term are showing as below:

AXSM' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.15   Med: 0.46   Max: 0.95
Current: 0.26

During the past 11 years, the highest Equity to Asset Ratio of Axsome Therapeutics was 0.95. The lowest was -1.15. And the median was 0.46.

AXSM's Equity-to-Asset is ranked worse than
77.09% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs AXSM: 0.26

Axsome Therapeutics Equity-to-Asset Historical Data

The historical data trend for Axsome Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Equity-to-Asset Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.61 0.18 0.33 0.33

Axsome Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.46 0.45 0.33 0.26

Competitive Comparison of Axsome Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Axsome Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Equity-to-Asset falls into.



Axsome Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Axsome Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=190.977/588.236
=0.32

Axsome Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=144.036/545.728
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axsome Therapeutics  (NAS:AXSM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Axsome Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (Axsome Therapeutics) Business Description

Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs director
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111

Axsome Therapeutics (Axsome Therapeutics) Headlines

From GuruFocus